TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Admission Berg Balance Scale score of 21 or greater~* 18 years of age or older~* Be able to understand and respond to simple verbal instructions in any language~* Be able to physically tolerate and actively participate in at least three, 30 minute weekly sessions in the ZeroG body weight support system~Exclusion Criteria:~* Cognitive deficits that would disrupt the ability to provide informed consent~* Admission Berg Balance Scale score less than 21~* Uncontrolled hypotension~* Uncontrolled hypertension~* Unstable skin structure (i.e. skin grafts, chest tubes)~* Unstable rib or lower extremity fractures~* Osteoporosis~* Active enteric infection control precautions~* New limb amputations~* Need for greater than 50% high flow oxygen~* Body weight greater than 450 pounds (structural limitations of the ZeroG body weight support system)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Body weight support system control group (Type: ACTIVE_COMPARATOR): In this arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system.
- Body weight support system with balance perturbations (Type: EXPERIMENTAL): Similar to the control group arm, participants will undergo their normal physical therapy treatment while using the ZeroG body weight support system, with the inclusion of 8 total balance perturbations each session, including 2 in the posterior, anterior, left lateral, and right lateral directions.
- Historical Standard of Care control (Type: NO_INTERVENTION): Retrospective anonymized Berg Balance Score data of stroke inpatients was collected from an institutional report for fiscal year 2018. 2018 was chosen as it preceded the implementation of the ZeroG body weight support system and reflects a no-intervention control baseline. This data was then filtered to show only patients with a Berg score of 21 or greater to match the study's inclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 65 years of age.~* Weight\> 50 kg and \<95 kg inclusive~* For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day 1.~* For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner\[s\] become pregnant during the full duration of the study.~* Willing, committed, and able to return for all clinic visits and complete all study-related procedures.~* Able to read, understand and willing to sign the informed consent form.~Exclusion Criteria:~* Initiation of a new exercise routine or major change to a previous exercise routine within 4 weeks prior to screening visit.~* Pregnant or breast-feeding women.~* Significant concomitant illness or history of significant illness such as cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease, or any other illness or condition that would adversely affect the subject's participation in this study.~* Hospitalization for any reason within 60 days of screening.~* Known history of Human Immunodeficiency Virus (HIV) antibody; and/or positive Hepatitis B surface antigen, and/or positive Hepatitis C antibody at the screening visit.~* Previous exposure to any therapeutic or investigational biological agent.~* History of alcohol or substance abuse within previous 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Dose 1 versus placebo
- Cohort 2 (Type: EXPERIMENTAL): Dose 2 versus placebo
- cohort 3 (Type: EXPERIMENTAL): Dose 3 versus placebo
- cohort 4 (Type: EXPERIMENTAL): Dose 4 versus placebo
- cohort 5 (Type: EXPERIMENTAL): Dose 5 versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with uncomplicated, essential hypertension~Exclusion Criteria:~* Severe hypertension~* History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm~* Liver, kidney, or pancreas disease~* Insulin dependent diabetes~* Allergy to certain medications used to treat high blood pressure~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18 and above;~* Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3) caused by infection with HPV types 16 and/or 18 confirmed at screening visit;~Exclusion Criteria:~* Biopsy-proven differentiated VIN;~* Any previous treatment for vulvar HSIL within 4 weeks prior to screening;~* Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;~* Pregnant, breastfeeding or considering becoming pregnant within 6 months following the last dose of investigational product;~* Immunosuppression as a result of underlying illness or treatment;~* Significant acute or chronic medical illness.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VGX-3100 + EP (Type: EXPERIMENTAL): Participants with histologically confirmed vulvar high-grade squamous intraepithelial lesion (HSIL) associated with human papilloma virus (HPV) 16 and/or 18, received four doses of 6 mg VGX-3100 as an intramuscular (IM) injection on Day 0, Week 4, Week 12, and Week 24 followed by electroporation (EP) using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.
- VGX-3100 + EP + Imiquimod (Type: EXPERIMENTAL): Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52. In addition, participants applied imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* completed primary TBE immunization + at least one booster immunization~* adults of both sexes between 18 and 60 years of age~* willingness to sign written informed consent form~Exclusion Criteria:~* age \< 18 and \> 60 years~* prior TBE infection~* Hepatitis A vaccination~* pregnancy and breast feeding~* acute infection on day of inclusion (day 0), body temperature \>37,9°C~* concomitant medications: systemic cortisone therapy, chemotherapy, immunosuppressive therapy 4 weeks prior to or during study~* administration of other vaccines 4 weeks before/after TBE vaccination~* planned surgery within 2 weeks before/after TBE vaccination~* Start of de-sensitization and the first 4 weeks of allergen dose escalation~* any contraindication to administration of FSME-Immun® vaccine according to manufacturer's instructions~* history of malignant disease within the last 5 years~* autoimmune diseases~* drug addictions~* plasma donors~* receipt of blood transfusions or immuno globulins within 3 month before study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Allergic patients (Type: EXPERIMENTAL): Allergic patients receive TBE booster vaccination
- Allergic patients with de-sensitization treatment (Type: EXPERIMENTAL): Allergic patients with de-sensitization treatment receive TBE booster vaccination
- Healthy controls (Type: ACTIVE_COMPARATOR): Healthy controls receive TBE booster vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CRESTOR Athero Imaging Head to Head IVUS Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical indication for coronary angiography~* Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1 lesion in a native coronary artery that has \>20% reduction in lumen diameter by visual estimation~* Left main coronary artery must have \<=50% reduction in lumen diameter by visual estimation~* LDL-C \>100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks; LDL-C \>80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks~Exclusion Criteria:~* Use of certain lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis.~* Patients who have symptoms consistent with moderate or greater severity of Congestive Heart Failure (CHF).~* Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin 20 mg (Type: EXPERIMENTAL): Rosuvastatin 20 mg distributed in 2-week run-in period
- Atorvastatin 40 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 40 mg distributed in 2-week run-in period
- Rosuvastatin 40 mg (Type: EXPERIMENTAL): Rosuvastatin 40 mg distributed in core 2-year study
- Atorvastatin 80 mg (Type: ACTIVE_COMPARATOR): Atorvastatin 80 mg distributed in core 2-year study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes diagnosed according to the report of WHO in 1999.~2. Age at onset between 25\~70 years.~3. Disease duration of less than 3 year.~4. No ketoacidosis within the first 6 months after diagnosis of diabetes.~5. GADA positive twice within one month.~6. Fasting C-peptide (FCP) level of 0.2 nmol/L or more.~Exclusion Criteria:~1. Insulin requirements more than 0.8 units/kg/day.~2. Evidence of chronic infection or acute infection affected blood glucose control within 4 weeks prior to visit 1.~3. History of any malignancy.~4. Pregnancy, breastfeeding or planned pregnancy within two years.~5. Secondary diabetes.~6. Congestive heart failure requiring pharmacologic treatment.~7. Renal disease or renal dysfunction or diabetic nephropathy suggested by serum creatinine levels≥1.5 mg/dL (132μmol/L) for males and ≥1.4mg/dL (123μmol/L) for females or abnormal creatinine clearance at Visit 1.~8. Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Patients will receive insulin therapy with sitagliptin.
- Insulin (Type: ACTIVE_COMPARATOR): Patients will receive insulin therapy without sitagliptin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Chronic HIV-1 infection~3. Antiretroviral treatment with either DRV/r (800/100 mg QD) or LPV/r (400/100 mg BID) monotherapy during at least 6 months prior to screening.~4. Fasting total cholesterol or LDL-cholesterol levels ≥ 200 and ≥130 mg/dL respectively, in the previous two consecutive tests obtained at least 4 weeks apart before screening.~5. Calculated creatinine clearance ≥ 60 mL/min, according to the Cockcroft-Gault formula.~6. Undetectable plasma HIV-1 RNA levels (\< 50 copies/mL) during at least 6 months prior to screening.~7. Adequate treatment adherence.~8. Absence of TDF or FTC resistances.~9. Written informed consent to participate into the study.~Exclusion Criteria:~1. Acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study~2. Lactating, pregnancy or fertile women willing to be pregnant.~3. Concomitant use of any drug with potential drug-drug interaction with DRV/r, LPV/r or TDF/FTC co-formulation at study entry.~4. Concomitant use of any lipid-lowering drugs at study entry.~5. Prior documented intolerance or hypersensitivity to TDF, FTC, LPV/r or DRV/r.~6. Therapies including interferon, interleukin-2, cytotoxic chemotherapy or immunosuppressors at study entry.~7. Acute or chronic renal documented pathologies.~8. Documented resistance to any of the study drugs (either genotypic or phenotypic)~9. Life expectancy less or equal to 1 year.~10. Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance.~11. Subjects currently taking part in any other clinical trial using an investigational product, with the exception of studies where the treatment studied have stopped for more than 12 weeks.~12. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TDF/FTC (3 months) + Placebo (6 months) (Type: EXPERIMENTAL): TDF/FTC (3 months) + Placebo (6 months)
- Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months) (Type: PLACEBO_COMPARATOR): Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes, including newly-diagnosed patients / those already receiving other anti-diabetic medications including GLP-1 analogues, who require treatment with liraglutide according to the clinical judgment of their treating physician~* Subjects who are capable of giving study-specific signed informed consent before any collection of information~Exclusion Criteria:~* Subjects with type 1 diabetes~* Subjects who are or have previously been on liraglutide~* Subjects who have previously been enrolled in the study~* Subjects who are participating in another clinical trial~* Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)~* Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve, HCV genotype 1b patients~* History of chronic HCV infection \> 6 months~* Aged at least 20 years~* HCV RNA of 10,000 IU/mL or greater~* Fibroscan examination \< 9.5 Kpa~* Negative serum or urine pregnancy test result (sensitivity of 25 mIU or better) for women with childbearing potential within the 24-hour period before the first dose of study drugs~* Female patients with childbearing potential must agree to use two reliable forms of effective non-hormonal contraception (i.e., condoms, cervical barriers, intrauterine device, spermicides, or sponge), at least 1 of which must be a physical barrier method, during treatment till end of follow up.~* A hormonal contraception (in lieu of non-hormonal) plus a physical barrier method can be used after end of treatment. All men with female partners of childbearing potential must use two reliable forms of effective contraception (combined) during treatment and till end of follow up~* Ability to participate and willingness to give written informed consent and to comply with the study restrictions.~Exclusion Criteria:~* Prior experience of IFN or direct antiviral agents (DAA)~* Hepatitis B virus or HIV co-infection.~* Patients with experience of ascites, esophageal varices, or other evidence of hepatic decompensation, and/or hepatocellular carcinoma.~* History of organ transplantation, except cornea transplantation.~* Hemoglobulin concentration \< 11 mg/dl~* Platelet count \< 75,000/mm3~* Albumin \< 3 mg/dL~* History of active malignancy within the last 5 years, with the exception of localized or in situ carcinoma (e.g., basal or squamous cell carcinoma of the skin)~* Poorly controlled diabetes (Hemoglobin A1c value ≥ 8.5%) and endocrine condition.~* Total bilirubin \>2 mg/dL, unless subject has a documented history of Gilbert's disease.~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 8-week arm (Type: EXPERIMENTAL): patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
- 12-week arm (Type: ACTIVE_COMPARATOR): patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete